Therapeutic potential of mouse bone marrow mesenchymal stromal cells transplantation in ameliorating of CCL4-induced liver damage (in vivo study)

  • 10 May 2022
  • Recently published Research - Pharmacy


Dima Joujeh, Abduljalil Ghrewaty, Chadi Soukkarieh, Adnan Almarrawi, Jamal Abdul Naser Darwicha

Published in

Cellular Therapy and Transplantation (CTT), Volume 11, No. 1, April 2022.



Stem cells therapy is a promising treatment for liver disease. In this study, the effect of bone marrow derived stem cells (BMSCs) in the treatment of CCl4 induced liver damage was investigated.

Methods: Balb/c mice were injected by (1 ml/kg body weight) of CCl4 twice a week for 7 weeks. Then, mice were intravenously injected with BMSCs (at the passage 0). At 4 weeks after transplantation, serum levels of ALT, ALP and albumin were measured, liver histopathology was performed, and enzyme-linked immunosorbent assay (Elisa) was carried out to detect the serum levels of IL-4 and IFN-γ.

Results: Compared with the PBS treated group, BMSC treated group presented the lower levels of ALT and ALP. It also induced positive changes in serum albumin. Histological studies were consistent with Biochemical results, suggesting an improvement in BMSCs treated group compared with PBS treated group. BMSC transplantation increased the production of IL-4 and IFN-γ compared to PBS-treated group.

In conclusion, our results demonstrated that syngeneic BMSCs transplantation could facilitate recovery from chemically induced liver damage, despite induction of an immune response. Therefore, BMSC transplantation may introduce a new concept for the treatment of liver diseases.

Keywords: Balb-c mice, liver damage, bone marrow stem cells, CCl4, cell transplantation.

Link to Read Full Paper